Influence of mutation in the regulatory domain of α-isopropylmalate synthase from Saccharomyces cerevisiae on its activity and feedback inhibition.

Isoamyl alcohol (i-AmOH) is produced from α-ketoisocaproate in the l-leucine biosynthetic pathway in yeast and controlled by the negative feedback regulation of α-isopropylmalate synthase (IPMS), which senses the accumulation of l-leucine. It is known that i-AmOH production increases when mutations in the regulatory domain reduce the susceptibility to feedback inhibition. However, the impact of mutations in this domain on the IPMS activity has not been examined. In this study, we obtained 5 IPMS mutants, encoding the LEU4 gene, N515D/S520P/S542F/A551D/A551V, that are tolerant to 5,5,5-trifluoro-dl-leucine. All mutant proteins were purified and examined for both IPMS activity and negative feedback activity by in vitro experiments. The results showed that not only the negative-feedback regulation by l-leucine was almost lost in all mutants, but also the IPMS activity was greatly decreased and the difference in IPMS activity among Leu4 mutants in the presence of l-leucine was significantly correlated with i-AmOH production.

Efficient production of L-lactic acid by Crabtree-negative yeast Candida boidinii.

Industrial production of L-lactic acid, which in polymerized form as poly-lactic acid is widely used as a biodegradable plastic, has been attracting world-wide attention. By genetic engineering we constructed a strain of the Crabtree-negative yeast Candida boidinii that efficiently produced a large amount of L-lactic acid. The alcohol fermentation pathway of C. boidinii was altered by disruption of the PDC1 gene encoding pyruvate decarboxylase, resulting in an ethanol production that was reduced to 17% of the wild-type strain. The alcohol fermentation pathway of the PDC1 deletion strain was then successfully utilized for the synthesis of L-lactic acid by placing the bovine L-lactate dehydrogenase-encoding gene under the control of the PDC1 promoter by targeted integration. Optimizing the conditions for batch culture in a 5 l jar-fermenter resulted in an L-lactic acid production reaching 85.9 g/l within 48 h. This productivity (1.79 g/l/h) is the highest thus far reported for L-lactic acid-producing yeasts.

Short-term intravenous interferon therapy for chronic hepatitis B.

AIM: To investigate the therapeutic efficacy of short-term, multiple daily dosing of intravenous interferon (IFN) in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. METHODS: IFN-beta was intravenously administered at a total dose of 102 million international units (MIU) over a period of 28 d in 26 patients positive for HBeAg and HBV-DNA. IFN-beta was administered at doses of 2 MIU and 1 MIU on d 1, 3 MIU twice daily from d 2 to d 7, and 1 MIU thrice daily from d 8 to d 28. Patients were followed up for 24 wk after the end of treatment. RESULTS: Six months after the end of the treatment, loss of HBV-DNA occurred in 13 (50.0%) of the 26 patients, loss of HBeAg in 9 (34.6%), development of anti-HBe in 10 (38.5%), HBeAg seroconversion in 8 (30.8%), and normalization of alanine aminotransferase (ALT) levels in 11 (42.0%). CONCLUSION: This 4-wk long IFN-beta therapy, which was much shorter than conventional therapy lasting 12 wk or even more than 1 year, produced therapeutic effects similar to those achieved by IFN-alpha or pegylated-IFN-alpha (peg-IFN). Fewer adverse effects, greater efficacy, and a shorter treatment period led to an improvement in patients' quality of life. IFN-beta is administered intravenously, whereas IFN-alpha is administered intramuscularly or subcutaneously. Because both interferons are known to bind to an identical receptor and exert antiviral effects through intracellular signal transduction, the excellent results of IFN-beta found in this study may be attributed to the multiple doses allowed by the intravenous route.

Metabolic engineering of Saccharomyces cerevisiae for efficient production of pure L-(+)-lactic acid.

We developed a metabolically engineered Saccharomyces cerevisiae, which produces optically pure L-lactic acid efficiently using cane juice-based medium. In this recombinant, the coding region of pyruvate decarboxylase (PDC)1 was completely deleted, and six copies of the bovine L-lactate dehydrogenase (L-LDH) genes were introduced on the genome under the control of the PDC1 promoter. To confirm optically pure lactate production in low-cost medium, cane juice-based medium was used in fermentation with neutralizing conditions. L-lactate production reached 122 g/L, with 61% of sugar being transformed into L-lactate finally. The optical purity of this L-lactate, that affects the physical characteristics of poly-L-lactic acid, was extremely high, 99.9% or over.

Metabolic engineering of Saccharomyces cerevisiae for efficient production of pure L-(+)-lactic acid.

We developed a metabolically engineered Saccharomyces cerevisiae, which produces optically pure L-lactic acid efficiently using cane juice-based medium. In this recombinant, the coding region of pyruvate decarboxylase (PDC)1 was completely deleted, and six copies of the bovine L-lactate dehydrogenase (L-LDH) genes were introduced on the genome under the control of the PDC1 promoter. To confirm optically pure lactate production in low cost medium, cane juice-based medium was used in fermentation with neutralizing conditions. L-lactate production reached 122 g/L, with 61% of sugar being transformed into L-lactate finally. The optical purity of this L-lactate, that affects the physical characteristics of poly-L-lactic acid, was extremely high, 99.9% or over.